Search
Bebtelovimab
go.drugbank.com/drugs/DB16755ApprovedWithdrawnin the US. … [L40328] Bebtelovimab was issued an emergency use authorization (EUA) by the FDA on February 11, 2022, for the treatment of mild-to-moderate COVID-19 in select patients.
Phenelzine
go.drugbank.com/drugs/DB00780ApprovedInvestigational[A15753] It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name of Nardil.
Categories: Monoamine Oxidase Inhibitors, Non-Selective, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeBaxdrostat
go.drugbank.com/drugs/DB19090ApprovedInvestigationalOn May 18, 2026, baxdrostat was approved by the FDA as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combination with other antihypertensive drugs [L56189]. … due to non-selective steroidal activities [A275513, A275514].
Synonyms: (+)-(r)-n-(4-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide, N-((8r)-5,6,7,8-tetrahydro-4-(1,2,3,4-tetrahydro-1-methyl-2-oxo-6-quinolinyl)-8-isoquinolinyl)propanamideCysteamine
go.drugbank.com/drugs/DB00847ApprovedInvestigationalMarketed by Recordati Rare Diseases Inc., CYSTADROPS® reduce the burden of multiple frequent medications normally administered to those with cystinosis.[L15601] … [L15606] Cysteamine eye drops are a practical and effective option for those affected by ocular cystinosis.
Insulin icodec
go.drugbank.com/drugs/DB16693ApprovedInvestigational[L51078]The US FDA subsequently approved insulin icodec in March 2026 for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. [L56102] … [L50758,A263818] Insulin icodec was approved by Health Canada in March 2024 for the treatment of adult patients with type 1 or 2 diabetes mellitus,[L50758] and was subsequently approved by the EMA in
Tridihexethyl
go.drugbank.com/drugs/DB00505ApprovedWithdrawnTridihexethyl is no longer available in the US market. … Tridihexethyl is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract.
Elosulfase alfa
go.drugbank.com/drugs/DB09051ApprovedInvestigationalElosulfase alfa is a synthetic version of the enzyme N-acetylgalactosamine-6-sulfatase. It was approved by the FDA in 2014 for the treatment of Morquio syndrome. … Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is marketed under the brand Vimizim™.
Synonyms: Recombinant human N-acetylgalactosamine-6-sulfatase, Recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS)Repaglinide
go.drugbank.com/drugs/DB00912ApprovedInvestigationalThe average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. … It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release.
Baclofen
go.drugbank.com/drugs/DB00181ApprovedInvestigationalAlthough originally designed in 1962 to treat epilepsy, baclofen was not effective in treating this condition but instead was shown to reduce spasticity in selected patients. … [A245338] Baclofen was reintroduced in 1971 as a treatment for spasticity and was later approved by the FDA in 1977.
International brands: Nu-BaclofenProducts: Co Baclofen Tablets 10mg, Co Baclofen Tablets 20mgAurothioglucose
go.drugbank.com/drugs/DB09121ApprovedWithdrawnContemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression in patients with rheumatoid arthritis [A32326]. … Aurothioglucose, also known as gold thioglucose, was formerly used to treat rheumatoid arthritis.